A 52-year-old male smoker with a 30 pack-year history presents with progressive dyspnea on exertion and chronic cough. Spirometry shows FEV₁/FVC ratio of 0.68 (post-bronchodilator), FEV₁ 45% predicted, and a normal DLCO. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has spirometric evidence of GOLD Stage 3 (severe) COPD: FEV₁/FVC < 0.70 (obstructive pattern) and FEV₁ 40–49% predicted. The normal DLCO excludes significant emphysema or interstitial lung disease as the primary pathology. ## Next Step Rationale **Key Point:** Once spirometry confirms COPD severity, the next step is **pharmacological and non-pharmacological management**, not further diagnostic testing. Triple therapy (ICS/LABA/LAMA) is indicated for GOLD Stage 3 COPD with exacerbation history or persistent symptoms. Pulmonary rehabilitation improves exercise capacity and quality of life. **High-Yield:** In a patient with confirmed obstructive airway disease (FEV₁/FVC < 0.70) and appropriate clinical history (smoking, dyspnea, cough), the diagnosis is established. Management follows GOLD guidelines; additional imaging or repeat spirometry delays evidence-based care. **Clinical Pearl:** Normal DLCO in a smoker with COPD suggests airway-predominant disease (chronic bronchitis phenotype) rather than emphysema; this does not change the immediate management strategy. ## Why Other Options Are Not Next Steps | Option | Rationale for Rejection | | --- | --- | | HRCT chest | Useful for phenotyping (emphysema vs. bronchitis) or excluding alternative diagnoses (bronchiectasis, ILD), but not the immediate next step once COPD is confirmed. Imaging is adjunctive, not primary management. | | Repeat spirometry after 4 weeks | Spirometry is already diagnostic. Repeating after a short trial of bronchodilators delays initiation of guideline-directed therapy. Bronchodilator response does not change COPD diagnosis or management tier. | | Bronchoscopy with BAL | No clinical or radiological suspicion of malignancy (no nodule, no hemoptysis). Bronchoscopy is invasive and not indicated for COPD diagnosis or routine assessment. | ## Management Algorithm ```mermaid flowchart TD A[Spirometry: FEV₁/FVC < 0.70]:::outcome --> B{COPD severity?}:::decision B -->|GOLD 1-2| C[LABA or LAMA monotherapy]:::action B -->|GOLD 3-4| D[Dual or triple therapy]:::action D --> E[Initiate ICS/LABA/LAMA]:::action E --> F[Pulmonary rehabilitation]:::action F --> G[Assess response & exacerbation risk]:::outcome ``` [cite:Harrison 21e Ch 298]